FivePrime and Pfizer Enter Oncology and Diabetes Collaboration

Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in vivo screens directed toward finding potential therapeutic protein products and antibody targets.

Upon the commencement of the collaboration, FivePrime will receive an up-front payment and an equity investment from Pfizer and three years of committed research funding. Pfizer will have exclusive worldwide rights to develop and commercialize certain products and targets discovered during the research term, in exchange for future milestones and royalties. Further details of the agreement have not been disclosed.

"Pfizer's commitment to biotherapeutics and its extensive development and commercialization capabilities are an ideal match for FivePrime’s powerful biologics discovery platform. This combination will increase the likelihood and speed of discovering and developing new biotherapeutics for patients in need," stated Lewis T. ("Rusty") Williams, MD, PhD, FivePrime's Founder and Executive Chairman.

FivePrime's existing investors made a co-investment in FivePrime in conjunction with Pfizer's equity purchase. "This is a very significant transaction for FivePrime," commented Gail Maderis, President and CEO of FivePrime. "It provides the financial runway to take several of our oncology products into clinical trials in addition to greatly expanding our discovery efforts."

A key component of the collaboration is FivePrime’s comprehensive, rapid protein discovery system. Its protein screening library contains essentially all human secreted proteins and their receptors, including many that are unavailable in public collections. FivePrime screens its protein library in both complex, primary cell assays and in high-throughput in vivo systems. The in vivo technology is also used for rapid validation of hits, significantly reducing the time from an idea to an Investigational New Drug.

"We are very excited about this research collaboration, as it will fill a core need for Pfizer's new biologics enterprise, the Biotherapeutics and Bioinnovation Center (BBC)," said BBC President Corey Goodman, PhD. "Our mission is to gain access to the best internal and external science and to achieve Pfizer's corporate ambition of becoming a global leader in biotherapeutics. The investment and partnership with FivePrime represents a key milestone in our efforts as we are confident it will generate therapeutic proteins and antibodies that will ultimately lead to innovative medicines for patients worldwide."

About FivePrime
FivePrime is a privately held protein therapeutics discovery and development company located in San Francisco's Mission Bay development. FivePrime's most advanced programs are in oncology, with its lead biotherapeutic (FP-1039) slated to enter clinical testing in 2008, and two additional products in advanced preclinical development. FivePrime has discovery collaborations with Boehringer Ingelheim in the field of rheumatoid arthritis and with Centocor in the field of pulmonary fibrosis and osteoarthritis to identify new biotherapeutics and antibody targets. For more information please visit www.fiveprime.com.

About Pfizer Inc. and the Biotherapeutics and Bioinnovation Center (BBC)
Pfizer Inc. is the world's largest research-based biomedical and pharmaceutical company, employing approximately 87,000 colleagues in more than 150 countries. In 2007, Pfizer earned $48.4 billion in revenues and invested $8.1 billion in research and development. The BBC is based in the San Francisco Bay Area of California and combines cutting-edge biology, new platform technologies, and advanced research tools to discover and develop new medicines. This new venture is a significant departure for Pfizer and the pharmaceutical industry. Located in one of the hubs of biotechnology, the BBC has the entrepreneurial spirit of biotech and will collaborate broadly with the academic, biotech, and venture communities to focus on discovering and developing new medicines. For more information please visit www.pfizer.com.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...